{
    "root": "72b2e981-03dd-465e-ad71-75395a2cc624",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "LUTRATE DEPOT",
    "value": "20250314",
    "ingredients": [],
    "indications": "LUTRATE DEPOT 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer.",
    "contraindications": "Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule ( 2 ). LUTRATE DEPOT 22.5 mg for 3 months administration, given as a single intramuscular injection every 12 weeks. ( 2.1 )",
    "warningsAndPrecautions": "LUTRATE® DEPOT is supplied as a kit consisting of a LEUPROLIDE ACETATE MIXJECT single-dose delivery system consisting of a vial with a Flip-Off seal containing sterile, white to off white lyophilized leuprolide acetate microspheres incorporated in a biodegradable polymer, a MIXJECT vial adapter containing the needle, and a pre-filled syringe containing clear sterile mannitol solution for injection, USP, 2 mL, pH 4.5 to 7.0.\n                  LUTRATE® DEPOT (leuprolide acetate for depot suspension) 22.5 mg – NDC 83831-134-01\n                  \n                     Storage\n                  \n                  Store at controlled room temperature at 20°-25°C (68°-77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "LUTRATE DEPOT is contraindicated in:\n                  \n                  \n                     \n                        Hypersensitivity\n                         LUTRATE DEPOT is contraindicated in individuals with known hypersensitivity to GnRH agonists or any of the excipients in LUTRATE DEPOT. Reports of anaphylactic reactions to GnRH agonists have been reported in the medical literature."
}